Humana is one of the largest health care insurance companies in the United States. The firm is well known for its group, individual, and Medicare Advantage insurance programs. The healthcare giant has a large exposure to government-run healthcare plans, with nearly 75% of customers in Medicaid, Medicare, or additional government commercial plans. It also offers additional services including home based service care, pharmacy solutions, and clinical offerings. Humana is based in Louisville, Kentucky and was founded in 1961.
Humana has maintained an impressive three-year growth rate of dividends of 15.4 percent, primarily due to its most recent increase. Humana currently ranks 4th in dividend yield within the large cap health care plans category. The quarterly dividend for the April payment will be $0.40 versus the prior year rate of $0.29 per share. Humana is not a member of our Top 100 Dividend Stocks. (see below).
The dividend will be paid at the new higher rate on April 28, 2017, to shareholders of record at close of business on March 31, 2017. Humana Inc. is currently priced at $208.14. Listed in the table below are the quarterly dividend payments since 2011.
Analysis of Humana is based upon our five key criteria for the Top 100 list, which include;
|Dividend Growth (3-6 year avg)||15.3%||129|
|S&P Financial Rating||BBB+||160|
|% Yield||3 Year Div. Growth Rate||6 Year Div. Growth Rate||SPS 2016||P/S Ratio||10 yr P/S Low||10 yr P/S High||5 yr low Yield %||5 yr max Yield %|
- Humana has paid out a dividend consecutively for the past 6 years.
- Humana maintains an investment grade rating of BBB+.
- Humana has maintained a three-year growth rate of dividends of 15.3 percent.
- Humana maintains a beta of 0.85, lower than the average company.
- Humana’s dividend yield is below that of the S&P 500 Index.
- Humana’s current dividend yield (0.78%) is below its five-year average historical dividend yield.
- Humana is trading above its ten-year average price/sales (P/S) ratio and at an elevated P/E ratio.
- Humana maintains a low payout ratio.
Latest Earnings & Overall Analysis:
Humana issued its earnings data on February 8th. The company reported $2.09 EPS for the Q4 quarter, topping the consensus estimate of $2.06 by $0.03. For full year 2016, earnings per share came in at an impressive $9.57, growth of nearly 18% year-over-year. Revenues inched up just up slightly, at 0.8% year-over-year to $13.46 billion for Q4. This was below most estimates. For full year 2016, the company reported total revenue of $54.96 billion. This was nearly flat from 2015’s full-year results.
Humana’s medical loss ratio, also known as the consolidated benefit ratio or the percentage of expenses against premium revenues, came in at just over 81% in Q4. This assisted profits as it came in below last year’s results by over 300 basis points, as the firm had fewer claims. Human’s government retail segment listed a revenue increase of 2% from last year. Much of this gain was driven by increased membership. For its group healthcare plan division, the firm’s revenue dropped by over 2% to $1.8 billion. The group was negatively affected by declining membership.
Within the healthcare services segment, total revenues were $6.3 billion, an impressive rise of 6% on a year-over-year basis. The star within this division was its mail order pharmacy business. Humana continues to maintain a solid balance sheet with cash and equivalents at just over $2 billion. The firm maintains a solid investment grade credit rating as well. Humana paid out dividends of nearly $45 million in the quarter. For the year, payouts to shareholders accounted for $172 million. With the mutual termination of the deal with Aetna, Humana will also receive a cash breakup fee of $1 billion, or $630 million after taxes.
The firm made several announcements in mid-February including offering positive guidance for full-year 2017 earnings per share. Humana guided earnings per share at an adjusted range of $10.80 to $11.00. This would result in a 14% increase in earnings from 2016. The healthcare company also plans to exit its individual commercial business in the healthcare exchange market for 2018. This was due to Humana witnessing an unbalanced risk pool, where claims were becoming more prevalent with more sick patients signing up. It currently offer services for clients in 11 states. The firm also announced a new share repurchase authorization, which was on hold after the merger plans were initiated, for $1.5 billion in share buybacks. The large dividend increase was also announced of $1.60 a share.
|Earnings per Share||$9.57||$8.44||$7.36||$7.73||$7.47|
|Earnings per Share 2017 (projected)||$10.90|
Based on the firm’s high exposure to government based plans, scant payout ratio, below average yield, high P/S & P/E ratios, Humana Inc. does not qualify as one of our Top 100 Dividend Stocks.
Please subscribe to our monthly premium newsletter to find out more about our favorite healthcare companies & which stocks are listed in our model portfolio.
Humana, Inc. Dividend Yield Historical Chart (Click to enlarge)
Chart Explanation: Dividend growth stocks may be viewed undervalued when the current yield is above historical readings for the past 5 years.